医薬品有効成分の世界市場 2024-2028

概要

医薬品有効成分市場は、2023年から2028年にかけて864億7,000万米ドル、予測期間中のCAGRは6.73%で成長すると予測されています。

当レポートでは、医薬品有効成分市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。開発におけるAPI製造シナリオの進化、タイプII医薬品マスターファイル（DMF）の増加、コア・コンピタンスに集中するニーズの高まりなどが市場を牽引しています。

本調査では、API製造におけるパラダイムシフトが、今後数年間の医薬品有効成分市場成長を促進する主要な理由の1つであると特定しています。また、特許行使の増加や高齢者人口の増加が市場の大きな需要につながると見込まれています。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 医薬品有効成分の世界市場（API）2018-2022
• 製造業タイプセグメント分析 2018-2022
• タイプセグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション製造タイプ別

• 市場セグメント
• 比較製造タイプ別
• キャプティブAPI：市場規模と予測 2023-2028
• 契約API：市場規模と予測 2023-2028
• 市場機会製造タイプ別

第7章 市場セグメンテーション：タイプ別

• 市場セグメント
• 比較：タイプ別
• 革新的なAPI：市場規模と予測 2023-2028
• 汎用API：市場規模と予測 2023-2028
• 市場機会：タイプ別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• アジア：市場規模と予測 2023-2028
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• インド：市場規模と予測 2023-2028
• 日本：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AbbVie Inc.
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd.
• Cadila Pharmaceuticals Ltd.
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• GlaxoSmithKline Plc
• Koninklijke DSM NV
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Manufacturing Type
• Exhibits6: Executive Summary - Chart on Market Segmentation by Type
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global active pharmaceutical ingredients market (API) 2018 - 2022 ($ billion)
• Exhibits19: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion)
• Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Manufacturing Type - Market share 2023-2028 (%)
• Exhibits31: Data Table on Manufacturing Type - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Manufacturing Type
• Exhibits33: Data Table on Comparison by Manufacturing Type
• Exhibits34: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits35: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits36: Chart on Captive APIs - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits39: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits40: Chart on Contract APIs - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%)
• Exhibits42: Market opportunity by Manufacturing Type ($ billion)
• Exhibits43: Data Table on Market opportunity by Manufacturing Type ($ billion)
• Exhibits44: Chart on Type - Market share 2023-2028 (%)
• Exhibits45: Data Table on Type - Market share 2023-2028 (%)
• Exhibits46: Chart on Comparison by Type
• Exhibits47: Data Table on Comparison by Type
• Exhibits48: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits49: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits50: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%)
• Exhibits51: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%)
• Exhibits52: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits53: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibits54: Chart on Generic APIs - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%)
• Exhibits56: Market opportunity by Type ($ billion)
• Exhibits57: Data Table on Market opportunity by Type ($ billion)
• Exhibits58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits59: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits60: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits61: Chart on Geographic comparison
• Exhibits62: Data Table on Geographic comparison
• Exhibits63: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits64: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits65: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits66: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits80: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits81: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on India - Market size and forecast 2023-2028 ($ billion)
• Exhibits88: Data Table on India - Market size and forecast 2023-2028 ($ billion)
• Exhibits89: Chart on India - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on India - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibits93: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits99: Market opportunity By Geographical Landscape ($ billion)
• Exhibits100: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• Exhibits101: Impact of drivers and challenges in 2023 and 2028
• Exhibits102: Overview on Criticality of inputs and Factors of differentiation
• Exhibits103: Overview on factors of disruption
• Exhibits104: Impact of key risks on business
• Exhibits105: Vendors covered
• Exhibits106: Matrix on vendor position and classification
• Exhibits107: AbbVie Inc. - Overview
• Exhibits108: AbbVie Inc. - Product / Service
• Exhibits109: AbbVie Inc. - Key news
• Exhibits110: AbbVie Inc. - Key offerings
• Exhibits111: Amneal Pharmaceuticals Inc. - Overview
• Exhibits112: Amneal Pharmaceuticals Inc. - Business segments
• Exhibits113: Amneal Pharmaceuticals Inc. - Key news
• Exhibits114: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibits115: Amneal Pharmaceuticals Inc. - Segment focus
• Exhibits116: Aurobindo Pharma Ltd. - Overview
• Exhibits117: Aurobindo Pharma Ltd. - Product / Service
• Exhibits118: Aurobindo Pharma Ltd. - Key offerings
• Exhibits119: Cadila Pharmaceuticals Ltd. - Overview
• Exhibits120: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibits121: Cadila Pharmaceuticals Ltd. - Key offerings
• Exhibits122: Cipla Ltd. - Overview
• Exhibits123: Cipla Ltd. - Business segments
• Exhibits124: Cipla Ltd. - Key news
• Exhibits125: Cipla Ltd. - Key offerings
• Exhibits126: Cipla Ltd. - Segment focus
• Exhibits127: Dr Reddys Laboratories Ltd. - Overview
• Exhibits128: Dr Reddys Laboratories Ltd. - Business segments
• Exhibits129: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibits130: Dr Reddys Laboratories Ltd. - Segment focus
• Exhibits131: GlaxoSmithKline Plc - Overview
• Exhibits132: GlaxoSmithKline Plc - Business segments
• Exhibits133: GlaxoSmithKline Plc - Key news
• Exhibits134: GlaxoSmithKline Plc - Key offerings
• Exhibits135: GlaxoSmithKline Plc - Segment focus
• Exhibits136: Koninklijke DSM NV - Overview
• Exhibits137: Koninklijke DSM NV - Business segments
• Exhibits138: Koninklijke DSM NV - Key news
• Exhibits139: Koninklijke DSM NV - Key offerings
• Exhibits140: Koninklijke DSM NV - Segment focus
• Exhibits141: Lupin Ltd. - Overview
• Exhibits142: Lupin Ltd. - Product / Service
• Exhibits143: Lupin Ltd. - Key news
• Exhibits144: Lupin Ltd. - Key offerings
• Exhibits145: Novartis AG - Overview
• Exhibits146: Novartis AG - Business segments
• Exhibits147: Novartis AG - Key offerings
• Exhibits148: Novartis AG - Segment focus
• Exhibits149: Pfizer Inc. - Overview
• Exhibits150: Pfizer Inc. - Product / Service
• Exhibits151: Pfizer Inc. - Key news
• Exhibits152: Pfizer Inc. - Key offerings
• Exhibits153: Sanofi SA - Overview
• Exhibits154: Sanofi SA - Business segments
• Exhibits155: Sanofi SA - Key news
• Exhibits156: Sanofi SA - Key offerings
• Exhibits157: Sanofi SA - Segment focus
• Exhibits158: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibits159: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibits160: Sun Pharmaceutical Industries Ltd. - Key offerings
• Exhibits161: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits162: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits163: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits164: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits165: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits166: Viatris Inc. - Overview
• Exhibits167: Viatris Inc. - Business segments
• Exhibits168: Viatris Inc. - Key news
• Exhibits169: Viatris Inc. - Key offerings
• Exhibits170: Viatris Inc. - Segment focus
• Exhibits171: Inclusions checklist
• Exhibits172: Exclusions checklist
• Exhibits173: Currency conversion rates for US$
• Exhibits174: Research methodology
• Exhibits175: Validation techniques employed for market sizing
• Exhibits176: Information sources
• Exhibits177: List of abbreviations

Abstract

The active pharmaceutical ingredients market is forecasted to grow by USD 86.47 bn during 2023-2028, accelerating at a CAGR of 6.73% during the forecast period. The report on the active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by evolving api manufacturing scenario in developing scenario, increasing number of type II drug master files (DMF), and growing need to focus on core competencies.

Technavio's active pharmaceutical ingredients market is segmented as below:

By Manufacturing Type

• Captive APIs
• Contract APIs

By Type

• Innovative APIs
• Generic APIs

By Geographical Landscape

• Asia
• North America
• Europe
• Rest of World (ROW)

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredients market growth during the next few years. Also, increasing patent exercises and increasing geriatric population will lead to sizable demand in the market.

The report on the active pharmaceutical ingredients market covers the following areas:

• Active pharmaceutical ingredients market sizing
• Active pharmaceutical ingredients market forecast
• Active pharmaceutical ingredients market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Manufacturing Type
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global active pharmaceutical ingredients market (API) 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global active pharmaceutical ingredients market (API) 2018 - 2022 ($ billion)
• 4.2 Manufacturing Type Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion)
• 4.3 Type Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Manufacturing Type

• 6.1 Market segments
• Exhibit 30: Chart on Manufacturing Type - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Manufacturing Type - Market share 2023-2028 (%)
• 6.2 Comparison by Manufacturing Type
• Exhibit 32: Chart on Comparison by Manufacturing Type
• Exhibit 33: Data Table on Comparison by Manufacturing Type
• 6.3 Captive APIs - Market size and forecast 2023-2028
• Exhibit 34: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Captive APIs - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%)
• 6.4 Contract APIs - Market size and forecast 2023-2028
• Exhibit 38: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Contract APIs - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Manufacturing Type
• Exhibit 42: Market opportunity by Manufacturing Type ($ billion)
• Exhibit 43: Data Table on Market opportunity by Manufacturing Type ($ billion)

7 Market Segmentation by Type

• 7.1 Market segments
• Exhibit 44: Chart on Type - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Type - Market share 2023-2028 (%)
• 7.2 Comparison by Type
• Exhibit 46: Chart on Comparison by Type
• Exhibit 47: Data Table on Comparison by Type
• 7.3 Innovative APIs - Market size and forecast 2023-2028
• Exhibit 48: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 49: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 50: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%)
• 7.4 Generic APIs - Market size and forecast 2023-2028
• Exhibit 52: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 53: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion)
• Exhibit 54: Chart on Generic APIs - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Type
• Exhibit 56: Market opportunity by Type ($ billion)
• Exhibit 57: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 59: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 60: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 61: Chart on Geographic comparison
• Exhibit 62: Data Table on Geographic comparison
• 9.3 Asia - Market size and forecast 2023-2028
• Exhibit 63: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 64: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 65: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 66: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.4 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.5 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 China - Market size and forecast 2023-2028
• Exhibit 79: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.8 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.9 India - Market size and forecast 2023-2028
• Exhibit 87: Chart on India - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on India - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on India - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on India - Year-over-year growth 2023-2028 (%)
• 9.10 Japan - Market size and forecast 2023-2028
• Exhibit 91: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.11 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 99: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 101: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 103: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 104: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 105: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 106: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 107: AbbVie Inc. - Overview
• Exhibit 108: AbbVie Inc. - Product / Service
• Exhibit 109: AbbVie Inc. - Key news
• Exhibit 110: AbbVie Inc. - Key offerings
• 12.4 Amneal Pharmaceuticals Inc.
• Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
• 12.5 Aurobindo Pharma Ltd.
• Exhibit 116: Aurobindo Pharma Ltd. - Overview
• Exhibit 117: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 118: Aurobindo Pharma Ltd. - Key offerings
• 12.6 Cadila Pharmaceuticals Ltd.
• Exhibit 119: Cadila Pharmaceuticals Ltd. - Overview
• Exhibit 120: Cadila Pharmaceuticals Ltd. - Product / Service
• Exhibit 121: Cadila Pharmaceuticals Ltd. - Key offerings
• 12.7 Cipla Ltd.
• Exhibit 122: Cipla Ltd. - Overview
• Exhibit 123: Cipla Ltd. - Business segments
• Exhibit 124: Cipla Ltd. - Key news
• Exhibit 125: Cipla Ltd. - Key offerings
• Exhibit 126: Cipla Ltd. - Segment focus
• 12.8 Dr Reddys Laboratories Ltd.
• Exhibit 127: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 128: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 129: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 130: Dr Reddys Laboratories Ltd. - Segment focus
• 12.9 GlaxoSmithKline Plc
• Exhibit 131: GlaxoSmithKline Plc - Overview
• Exhibit 132: GlaxoSmithKline Plc - Business segments
• Exhibit 133: GlaxoSmithKline Plc - Key news
• Exhibit 134: GlaxoSmithKline Plc - Key offerings
• Exhibit 135: GlaxoSmithKline Plc - Segment focus
• 12.10 Koninklijke DSM NV
• Exhibit 136: Koninklijke DSM NV - Overview
• Exhibit 137: Koninklijke DSM NV - Business segments
• Exhibit 138: Koninklijke DSM NV - Key news
• Exhibit 139: Koninklijke DSM NV - Key offerings
• Exhibit 140: Koninklijke DSM NV - Segment focus
• 12.11 Lupin Ltd.
• Exhibit 141: Lupin Ltd. - Overview
• Exhibit 142: Lupin Ltd. - Product / Service
• Exhibit 143: Lupin Ltd. - Key news
• Exhibit 144: Lupin Ltd. - Key offerings
• 12.12 Novartis AG
• Exhibit 145: Novartis AG - Overview
• Exhibit 146: Novartis AG - Business segments
• Exhibit 147: Novartis AG - Key offerings
• Exhibit 148: Novartis AG - Segment focus
• 12.13 Pfizer Inc.
• Exhibit 149: Pfizer Inc. - Overview
• Exhibit 150: Pfizer Inc. - Product / Service
• Exhibit 151: Pfizer Inc. - Key news
• Exhibit 152: Pfizer Inc. - Key offerings
• 12.14 Sanofi SA
• Exhibit 153: Sanofi SA - Overview
• Exhibit 154: Sanofi SA - Business segments
• Exhibit 155: Sanofi SA - Key news
• Exhibit 156: Sanofi SA - Key offerings
• Exhibit 157: Sanofi SA - Segment focus
• 12.15 Sun Pharmaceutical Industries Ltd.
• Exhibit 158: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 159: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 160: Sun Pharmaceutical Industries Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 165: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Viatris Inc.
• Exhibit 166: Viatris Inc. - Overview
• Exhibit 167: Viatris Inc. - Business segments
• Exhibit 168: Viatris Inc. - Key news
• Exhibit 169: Viatris Inc. - Key offerings
• Exhibit 170: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 171: Inclusions checklist
• Exhibit 172: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 173: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 174: Research methodology
• Exhibit 175: Validation techniques employed for market sizing
• Exhibit 176: Information sources
• 13.5 List of abbreviations
• Exhibit 177: List of abbreviations